On October 1, 2026 RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, reported the publication of a peer-reviewed case series in Case Reports in Oncology from researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The publication describes two patients with locally advanced pancreatic cancer (LAPC), whose tumors were not surgically removable due to significant complex blood vessel involvement despite receiving extensive prior treatment. Both patients underwent chemotherapy utilizing TAMP-mediated local intra-arterial gemcitabine delivery enabled by RenovoCath. Notably, both patients demonstrated tumor treatment response with reductions in CA 19-9, a marker used to monitor disease activity in pancreatic cancers, and favorable changes on imaging, including resolution of vascular narrowing, without major procedural complications.
"Locally advanced pancreatic cancer remains one of the most difficult cancers to treat, and patients have limited options when standard systemic therapies, like intravenous chemotherapy, are no longer effective," said Gregory Tiesi, MD, FACS, FSSO, Chief of Surgical Oncology for the Southern Region and Medical Director of Hepatobiliary Surgery at Hackensack Meridian Health Jersey Shore University Medical Center, and lead author of the case series. "This case illustrates that gemcitabine can potentially be safely delivered at the local level via the TAMP platform in patients with complex vascular anatomy and adds to the peer-reviewed evidence supporting further utilization and evaluation of RenovoCath." Hackensack Meridian Health Jersey Shore University Medical Center has been using the TAMP Platform with the RenovoCath device in its oncology program for over a year.
"Independent, peer-reviewed publications such as this case series provide important clinical evidence supporting the potential of our novel, targeted drug-delivery approach," said Ramtin Agah, MD, RenovoRx’s Chief Medical Officer, Executive Chairman, and Founder. "These findings strengthen the scientific rationale for our drug-delivery platform and support our broader mission to bring meaningful new options to patients with difficult-to-treat tumors, especially as promising pancreatic treatments emerge that could be delivered via TAMP enabled by RenovoCath."
Publication Details
Title: Trans-Arterial Micro Perfusion in Locally Advanced Pancreatic Cancer: A Case Series and Review of Evidence
Journal: Case Reports in Oncology
Lead Author: Gregory Tiesi, MD, FACS, FSSO
Institution: Hackensack Meridian Health Jersey Shore University Medical Center
(Press release, Renovorx, OCT 1, 2026, View Source [SID1234671237])